Cumberland closes $100M Apotex deal, pays $1.50 special dividend, reports Q2 loss

CUMBERLAND PHARMACEUTICALS INC

Closed $100M strategic transaction with Apotex Health; received $111M total including inventory and transition services.
Paid special cash dividend of $1.50 per share on July 31, 2026 to shareholders of record July 23.
Q2 2026 loss from continuing operations $3.1M; net loss $4.1M; cash $4M; retired $5.2M credit line.
Phase 2 ifetroban in DMD showed biomarker evidence of cardiac protection; cancer metastasis study met safety endpoint.
Metastatic recurrence 17% ifetroban vs 50% placebo (p=0.09); deaths from metastasis 0% vs 30% (p=0.037).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.